SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia
May 16, 2023 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
May 11, 2023 16:12 ET
|
SELLAS Life Sciences Group, Inc.
Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient...
SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study
May 04, 2023 08:30 ET
|
SELLAS Life Sciences Group, Inc.
- 72 Acute Myeloid Leukemia and Lymphoma High-Risk Advanced Patients Enrolled: 94% Alive at Last Assessment Indicating Favorable Survival Benefit - - Long-Term Complete Remission and Significant Bone...
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
April 26, 2023 16:01 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
April 20, 2023 08:30 ET
|
SELLAS Life Sciences Group, Inc.
– GFH009 showed strong anti-tumor effect and clinical and biological efficacy; PK profile supports anticipated once weekly dosing – – GFH009 demonstrated a favorable tolerability profile with no dose...
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
April 18, 2023 08:30 ET
|
SELLAS Life Sciences Group, Inc.
Next IDMC Meeting Scheduled for Q3 2023 REGAL on Track for Interim Analysis by Late 2023/Early 2024 NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)...
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023 16:11 ET
|
SELLAS Life Sciences Group, Inc.
Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and...
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
March 07, 2023 08:30 ET
|
SELLAS Life Sciences Group, Inc.
Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting Immune Response Translated...
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
February 24, 2023 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
February 23, 2023 16:01 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of...